VAPB antibody (AA 51-150)
Quick Overview for VAPB antibody (AA 51-150) (ABIN705536)
Target
See all VAPB AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 51-150
-
Cross-Reactivity
- Rat
-
Predicted Reactivity
- Human,Mouse,Cow,Sheep,Pig,Horse,Chicken,Rabbit
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human VAPB
-
Isotype
- IgG
-
-
-
-
Application Notes
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Expiry Date
- 12 months
-
-
- VAPB (VAMP (Vesicle-Associated Membrane Protein)-Associated Protein B and C (VAPB))
-
Alternative Name
- VAPB
-
Background
-
Synonyms: ALS 8, ALS8, D2Abb2e, UNQ484/PRO983, Vamp 33b, VAMP associated 33 kDa protein, VAMP associated protein B and C, VAMP associated protein B, VAMP associated protein B/C, VAMP associated protein C, VAMP B, VAMP B VAMP C, VAMP B/VAMP C, VAMP C, VAMP vesicle associated membrane protein associated protein B and C, Vamp33b, VAMPB, VAMPB/VAMPC, VAMPC, VAP 33b, VAP B, VAP B/VAP C, VAP C, VAP33b, VAPB/VAPC, VAPC antibody Vesicle associated membrane protein associated protein B and C, Vesicle associated membrane protein associated protein B/C, VAPB_HUMAN.
Background: VAPB contains 1 MSP domain and it may play a role in vesicle trafficking. Defects in VAPB are a cause of proximal adult autosomal dominant spinal muscular atrophy [MIM:182980], also called late onset spinal muscular atrophy Finkel type. Spinal muscular atrophies are neurodegenerative disorders characterized by degeneration of lower motor neurons, leading to progressive paralysis muscular atrophy. This form is a late adult onset form of the disease (after age 20 years). The patients show a benign course, most of them remaining ambulatory 10 to 40 years after clinical onset.
-
Gene ID
- 9217
-
Pathways
- ER-Nucleus Signaling
Target
-